SPHK1 and ovarian carcinoma: Overall, our data uncovered a previously unrecognized oncogenic mechanism of how SPHK1‐packaged EVs upregulate S1P in the ovarian cancer microenvironment, enhancing immune suppression through T cell exhaustion.